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Abstract
Aim: Pancreatic neuroendocrine tumors (pNETs) can occur 
in patients with a familial syndrome either as multiple endo-
crine neoplasia type 1 (MEN-1) or as sporadic tumors. Endo-
scopic ultrasound (EUS) has become one of the first-line in-
vestigations for pNET characterization. The ultrasonograph-
ic features of pNETs may differ depending on the familial 
versus sporadic pathogenesis of the tumor. Therefore, the 
EUS findings could help and direct the definition of a pNET 
with an impact on the most appropriate diagnostic and ther-
apeutic patient management. Methods: In this single-center 
retrospective study, we reviewed the EUS features of 94 
pNETs from 37 MEN-1 patients and 15 pNETs from 11 spo-
radic disease patients at the time of their first EUS assess-
ment. We analyzed the most relevant morphological and ul-
trasonographic characteristics of the tumors and compared 
the findings between the 2 patient groups. Results: Patients 
with MEN-1 more likely present with multiple pNETs than 
patients with sporadic disease. Sporadic pNETs are usually 
much bigger than those due to MEN-1. Moreover, pNETs are 
more heterogeneous in patients with sporadic disease than 
in those with MEN-1. No statistical difference with regard to 
definition of the margins, morphology, and vascularization 
of the pNETs appears between the 2 groups. Conclusions: 
Patients with sporadic disease usually present with bigger 
and more heterogeneous pNETs than patients with MEN-1, 
who tend to present with a higher number of lesions. EUS 
can facilitate the precise characterization of a pNET, and the 
ultrasonographic features of the lesion can help and distin-
guish MEN-1-related versus sporadic disease.
© 2018 S. Karger AG, Basel
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Introduction
Neuroendocrine tumors represent a heterogeneous 
group of neoplasms from a biological, anatomical, and 
clinical point of view. Approximately, 5% of all neuroen-
docrine tumors originate from the pancreas and the esti-
mated incidence of pancreatic neuroendocrine tumors 
(pNETs) is 0.32/100,000/year [1]. From a pathogenetic 
perspective, pNETs can occur in patients with a familial 
syndrome or they can be sporadic as well [2]. Among the 
familial syndromes potentially leading to the develop-
ment of a pNET, multiple endocrine neoplasia type 1 
(MEN-1) is the definitely most frequent condition, fol-
lowed by von Hippel-Lindau disease, neurofibromatosis 
1 (von Recklinghausen disease), and the tuberous sclero-
sis complex [3]. The genetic background of the pNET de-
termines some differences in the diagnostic and thera-
peutic approach and dictate specifically targeted follow-
up plans. In such a setting, all investigations and 
techniques that can help with the determination of the 
familial rather than sporadic nature of the pNET are valu-
able.
In MEN-1 patients, pNETs occur in 30–80% of the cas-
es and may either secrete or not secrete hormones [4]. 
Moreover, the age of pNET onset is earlier in MEN-1 pa-
tients than in the patients with sporadic disease [5]. 
Though recommendations and guidelines have been 
published, the optimal managements of pNETs in MEN-
1 still remain controversial, especially with regard to the 
nonfunctioning tumors [4, 6, 7].
In the last decade, endoscopic ultrasound (EUS) has 
become one of the first-line imaging investigations for the 
characterization of pNETs [8, 9] and has a clearly defined 
role in the multidisciplinary diagnostic approach to pNET 
[10]. In experienced hands, EUS has sensitivity for pNETs 
ranging between 80 and 90% and specificity above 95% 
[11, 12]. In MEN-1 patients, EUS appears to be the most 
sensitive method for the detection of pNETs even when 
they are pretty small in size [4, 13–15]. The diagnostic 
value of EUS can go beyond this aspect, as such a tech-
nique may help with the retrieval of histological or cyto-
logical specimens for pathology examination. Moreover, 
the EUS features of a pNET might differ depending on the 
familial versus sporadic nature of the tumor and can di-
rect the subsequent steps of tumor diagnosis and localiza-
tion. Therefore, the EUS findings by themselves might 
help and direct the accuracy of the definition of a pNET 
at the time of its first detection, with a possible impact on 
the most appropriate diagnostic and therapeutic manage-
ment of the patient found to carry the lesion. 
In our study, we have collected, analyzed, and com-
pared the EUS features of pNETs occurring in a single-
center series of patients with MEN-1 versus those of 
pNETs occurring sporadically.
Methods
In this single-center retrospective study, we have collected, re-
viewed, and analyzed the EUS characteristics of 94 pNETs from 37 
patients with MEN-1 and 15 pNETs from 11 patients with spo-
radic disease at the time of their first EUS assessment (Table 1). 
The patients consecutively attended our institution over a 5-year 
time period (from September 2002 to July 2007).
EUS was carried out by 2 investigators using a Pentax  FG-32UA 
and FG-36UX endosonoscope (Pentax Corporation, Tokyo, 
 Japan) with a longitudinal 7.5 MHz sector array in combination 
with a Hitachi EUB-420 or Hitachi EUB-525 computational sys-
tem (Hitachi Medical Corporation, Tokyo, Japan) [16]. The vas-
cularization of the tumors was assessed with duplex ultrasonogra-
phy after a careful optimization of the Doppler technique and an 
appropriate gain setting for avoiding the appearance of noise.
Patients underwent EUS with conscious sedation. All EUS 
procedures were carried out as per the appropriate diagnostic 
management of the patients and were uneventful with regard to 
the occurrence of adverse events. With the goal of defining the 
EUS features of MEN-1-related versus sporadic pNETs, we have 
reviewed the most relevant morphological and ultrasonographic 
aspects of the tumors as described in the EUS reports and com-
pared the findings between the 2 patient groups. First of all, the 
number and the size of the tumors have been recorded. Then, the 
definition of the margin (well defined versus not well defined), the 
morphology (round/oval versus speckled), the appearance (ho-
mogeneous versus heterogeneous), and the vascularization (hy-
pervascular versus non-hypervascular) of the tumors have been 
evaluated.
The relevant data have been subsequently anonymized and 
stored in a password-protected system. The statistical evaluation 
of the data has been carried out using the analysis of variance when 
assessing the pNET maximum diameter, taking a p value <0.05 
as the cutoff for statistical significance. The EUS characteristics of 
the pNETs, including the number of lesions detected in each pa-
tient, have been analyzed using the Barnard’s test, taking again a p 
value <0.05 as the cutoff for significance. Barnard’s test is an exact 
unconditional nonparametric test for the analysis of contingency 
tables, which uses a more computationally intensive algorithm for 
creating a rejection region [17], finally representing a more power-
ful alternative to Fisher’s exact test.
This retrospective study has been carried out in accordance 
with the principles of the Declaration of Helsinki.
Results
Our study shows that, at the time of the first EUS de-
tection of a pNET, patients with MEN-1 appear more 



























   
   
   
   
   
   
   
   
























Table 1. Clinicopathological features of 48 patients with one or more pNETs occurring in the setting of MEN-1 or as sporadic disease
Patient Age Number of tumors Maximum diameter, mm Clinicopathological characterization
Patients with MEN-1
1 32 6 21 Nonfunctioning
2 50 4 14 Nonfunctioning
3 77 1 10 Nonfunctioning
4 35 2 10 Nonfunctioning
5 38 4 5 Nonfunctioning
6 47 2 7 Nonfunctioning
7 19 4 14 Nonfunctioning
8 45 2 12 Nonfunctioning
9 25 2 6 Nonfunctioning
10 52 2 6 Insulinoma, nonfunctioning
11 18 1 4 Insulinoma
12 39 2 6 Nonfunctioning
13 34 1 5 Insulinoma
14 35 1 4 Nonfunctioning
15 50 2 12 Gastrinoma
16 51 6 12 Nonfunctioning
17 58 2 26 Insulinoma, nonfunctioning
18 65 5 12 Nonfunctioning
19 33 2 11 Nonfunctioning
20 29 5 26 Insulinoma, nonfunctioning
21 50 2 13 Nonfunctioning
22 46 1 5 Nonfunctioning
23 28 2 4 Nonfunctioning
24 48 6 12 Nonfunctioning
25 38 1 5 Gastrinoma
26 47 2 10 Gastrinoma, nonfunctioning
27 38 1 13 Nonfunctioning
28 52 2 25 Gastrinoma
29 23 3 8 Nonfunctioning
30 72 4 14 Nonfunctioning
31 57 1 18 Insulinoma
32 47 2 3 Nonfunctioning
33 51 5 8 Gastrinoma, insulinoma
34 26 1 4 Nonfunctioning
35 41 3 5 Nonfunctioning
36 35 1 8 Nonfunctioning
37 56 1 6 Nonfunctioning
Patients with sporadic disease
1 63 1 8 Nonfunctioning
2 68 1 60 Nonfunctioning
3 63 2 6 Nonfunctioning
4 59 3 24 Nonfunctioning
5 26 1 65 Nonfunctioning
6 29 2 45 Insulinoma
7 69 1 7 Glucagonoma
8 66 1 14 Nonfunctioning
9 77 1 25 Nonfunctioning
10 38 1 9 Nonfunctioning
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patients with the sporadic disease (2.5 vs. 1.4 tumors/
patient). Despite a pretty well-defined trend, such find-
ing did not reach statistical significance (p = 0.163). On 
the contrary, pNETs occurring in patients with sporadic 
disease tend to be significantly bigger than those arising 
in the setting of MEN-1 (p > 0.001) and, more in the spe-
cific, the sporadic pNETs are 3 times bigger than the 
MEN-1-related lesions (23 vs. 7 mm; Fig. 1). With re-
gard to the tumor size, patients with sporadic disease 
also display a much greater variability than patients with 
MEN-1, presenting with lesions, which range from 4 to 
65 mm versus 3 to 26 mm. In sporadic disease patients, 
about half of the lesions had a maximum diameter be-
tween 10 and 30 mm and about a quarter of the lesions 
had a much bigger size, with maximum diameter above 
40 mm. In patients with MEN-1, two thirds of the pNETs 
had a diameter smaller than 10 mm, with a non-negligi-
ble portion of them being just at the size limit for detec-
tion. Only very few lesions had a maximum diameter 
above 20 mm and none of them was close to 30 mm in 
size.
In patients with sporadic disease, the tumors appear 
to be significantly more heterogeneous than in patients 
with MEN-1 (Table 2). The large majority of MEN-1-re-
lated pNETs have a homogeneous appearance. An illus-
trative EUS picture of homogenous versus heteroge-
neous pNET is provided (Fig. 2a, b). On the contrary, in 
terms of the features concerning their EUS appearance, 
there is no statistical difference with regard to the defini-
tion of the margins, the morphology, and the vascular-
ization of the pNETs between the 2 groups. However, the 
observation that 3 quarters of pNETs arising in MEN-1 
patients have well-defined margins is remarkable, also 
considering the fact that the rate between lesions with 
well-defined versus not well-defined margins in sporad-
ic disease patients is much more equilibrated. However, 
such observation did not achieve any statistical signifi-
cance in our patient population. Finally, it may be worth 
noticing that almost all pNETs have a round/oval shape 
and appear to be hypervascular regardless of their patho-
genesis.
Discussion
The diagnosis of pNETs is affected by a number of 
relevant challenges, which include the pathogenetic na-
ture, the localization, the definition of the number of 
the tumors, and first of all their identification. These 
issues probably arise in a more striking way when the 
pNET does not secrete any hormone leading to a spe-
cific endocrine syndrome. In such a challenging setting, 
many biochemical markers or radiological techniques 
can be of value and should be used with the goal of 
clarifying in the most precise way the disease, as this 
point has an extremely important role for the establish-
ment of the best plan of surgical and/or medical treat-

















Fig. 1. Comparison of the size of pNETs detected by EUS in pa-
tients with MEN-1 (MEN) and in patients with sporadic disease 
(Sporadic). p value <0.001.
Table 2. Analysis of the most relevant EUS features of pNETs in 
patients with MEN-1 (MEN) and in patients with sporadic disease 
(Sporadic).
MEN Sporadic Barnard’s test,
p value
Well defined 75 8 0.058Not well defined 19 7
Round/oval 92 14 0.383Speckled 2 1
Homogeneous 74 3 <0.001Heterogeneous 20 12



























   
   
   
   
   
   
   
   
























pNETs occurring in patients with a familial syndrome, 
like MEN-1, an early diagnosis is not only necessary for 
treating the patients on time but also extremely useful 
for defining the times of the successive follow-up as-
sessments and the screening of the family members 
[18–20].
With the optimization of the materials and techniques, 
EUS is progressively assuming the prominent position as 
first choice imaging procedure for the assessment of the 
pancreas in MEN-1 patients, being superior to CT, MRI, 
and somatostatin receptor scintigraphy [21, 22]. In such 
patient population, somatostatin receptor scintigraphy is 
considered being the most reliable method for the detec-
tion of metastatic disease [4]. A possible limitation of EUS 
sensitivity for the detection of pNETs may be represented 
by the localization of the tumor, as the lesions localized in 
the tail of the pancreas might remain hidden, especially if 
they are small in size. The high sensitivity and high spec-
ificity of EUS for the detection of pNETs and its value for 
the ultrasonographic characterization of the tumor obvi-
ously depend very much on the experience and ability of 
the investigator. Furthermore, its cost effectiveness is an 
additional factor supporting the increasing use of this in-
vestigation [23]. Even though the availability of EUS has 
dramatically spread in the last decade and the technique 
is now very largely used in the third-level and many sec-
ond-level hospitals, the unfortunate possibility of this in-
vestigation being not performed in the work-up of a sus-
picious pNET still exists and may depend on many fac-
tors.
In our study population, pNETs tend to be more nu-
merous (almost twice) in patients with MEN-1 than in 
those with sporadic disease, which is a predictable obser-
vation if we consider the pathogenesis of MEN-1-related 
versus sporadic lesions. This finding lacks statistical sig-
nificance and can be affected by the size of the study pop-
ulation, which might not be large enough for confirming 
such observation also from a statistical point of view, and 
by the fact that our EUS study takes into consideration 
only the first investigation performed for each patient, 
thus ignoring the very likely subsequent detection of ad-
ditional lesions overtime with the successive EUS assess-
ments. However, once a pNET is disclosed at EUS for the 
first time in a MEN-1 patient, it appears to be probable 
that another or even more other pancreatic lesions are 
already detectable. On the other hand, sporadic pNETs 
are roughly 3 times bigger than those detected in MEN-1 
patients and such a finding achieved a very strong statisti-
cal significance in our study population. While MEN-
1-related pNETs have usually a sub-centimeter diameter, 
sporadic pNETs often present with a diameter close to or 
bigger than 2 cm.
With regard to the ultrasonographic features of the 
pNETs, only the heterogeneous versus the homoge-
neous appearance of the tumor seems to have a statisti-
cal relevance in the distinction between sporadic and 
MEN-1-related tumors. While sporadic pNETs are of-
ten heterogeneous, the lesions observed in MEN-1 pa-
tients are often homogeneous. To the best of our knowl-
edge, a definite explanation for such EUS difference be-
tween the 2 patient groups is not available, though 
maybe the presence of areas of necrosis arising in the 
largest tumors might account for some intra-lesion ul-
trasonographic heterogeneity [24]. Interestingly and 
possibly somehow linked to this last observation, the 
majority of pNETs arising in MEN-1 patients have 
ba
Fig. 2. An illustrative EUS picture of a homogeneous pNET (a) of a patient with MEN-1 and a heterogeneous 
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well-defined margins, while sporadic pNETs can equal-
ly present either with well-defined or not well-defined 
margins. However, the mild difference affecting the 
characteristics of the margins of the pNETs of the 2 pa-
tient groups did not achieve any statistical significance 
in our patient population, and maybe a comparison in 
other, or larger, patient populations might lead to a bet-
ter definition of the clinical relevance of such EUS fea-
ture. Regardless of their pathogenesis, almost all pNETs 
have a round/oval shape and are hypervascular, high-
lighting a specific pattern that virtually characterizes 
the neuroendocrine neoplasms originating from Lang-
erhans islet. We are of the opinion that a larger and 
multicenter patient population could elucidate further 
the EUS features of pNETs and we believe that a con-
firmation of our original data could increase the clinical 
relevance of this set of observations. Over and above the 
pNETs ultrasonographic characteristics observed 
through EUS, such a sensitive and specific investigation 
also represents a reliable and effective support for per-
forming a lesion biopsy, with an obvious subsequent 
clinically relevant impact in terms of diagnostic charac-
terization, pathogenetic definition, and prognosis of the 
pNET [25–27]. Moreover, EUS can also be associated 
to radiofrequency ablation of pancreatic tumors, in-
cluding those of neuroendocrine origin [28].
In conclusion, EUS can help with the precise charac-
terization of pNETs, including the definition of ultraso-
nographic features, which can distinguish MEN-1-relat-
ed versus sporadic disease. At the time of the first EUS 
assessment of a patient with a pNET, the presence of a 
single big heterogeneous lesion suggests facing most like-
ly a sporadic disease while the detection of 1 or more sub-
centimeter lesions with homogeneous aspect and well-
defined margins is more likely to characterize a pNET 
related to MEN-1.
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